
Las Vegas tourism drops sharply as some visitors claim 'casinos are empty' amid rising costs
The latest statistics from the Las Vegas Convention and Visitors Authority (LVCVA) show that only 3.1 million people visited in June, which is down 11.3% compared to last year.
The hotel industry is feeling the burn of fewer visitors, with occupancy dropping 6.5% while average daily room rates have lowered to $163.64 – down 6.6%, according to the LVCVA.
Even the Harry Reid Airport has shown a decline, dropping 4.1% in year-to-date decline compared to the same time last year, according to the website.
Tom Reeg, Caesars Entertainment CEO, shared that it would be a "soft summer" on a recent earnings call, according to local reports.
A recent X user claimed to have family members living in Las Vegas. The person posted, "They say casinos are empty … People are being laid off … There is no tourism."
Another X user shared a photo of an empty casino, captioning the post, "Las Vegas is dead, bro."
In April, three lawsuits were filed against two resorts on the Las Vegas strip for incidents that occurred in the summer of 2024, Fox News Digital previously reported.
Attorney Brian Virag, founder and CEO of My Bed Bug Lawyer, is representing the plaintiffs in these cases and commented on the situation.
"We wanted to not only make sure to represent them, but also to bring awareness that bedbugs in Las Vegas hotels are a real problem," Virag told Fox News Digital recently.
Many Reddit users have drawn attention to tourism issues in Sin City, posting thoughts in the "r/lasvegas" forum.
"While the economy is going downhill, the strip nickel and diming folks [sic] is gonna result in this, and it's gonna get worse," wrote one user.
Another person said, "Slow season in Vegas, no people, no conferences in summer, and it's hot."
"I think it's worth noting [that] last June, the NHL awards and NHL draft were both in town," one user pointed out. "I went to both and met a ton of people and none of them were from Vegas, so that would account for a lot of tourism during that time."
Another Redditor declared, "Vegas will never recover."
Mallory Dumond, Travelmation adviser and supervisor, recently told Fox News Digital the cost of visiting Vegas has increased over the past year.
"Despite the high price tags, with proper planning, you can still ensure value, comfort and memorable moments if you're thinking of visiting Vegas," she said.
Dumond shared a few tips for those seeking to visit the Gambling Capital of the World.
"Opt for a Sunday through Thursday stay if your schedule will allow. Often, you can find 5-star rooms at half the weekend rate! Same suite, same view, smarter timing."
Dumond said that hitting nice restaurants can be more affordable during the day for lunch as opposed to dinner — and that visitors should take advantage of tasting menus or happy hours.
"For those who don't want to stomach the bloated costs in Las Vegas, I encourage clients to consider Atlantic City, New Jersey, for a more affordable casino-and-beach alternative with major resort brands and entertainment," said Drummond.
"Napa Valley, California, is ideal for a laid-back, elevated vacation experience with delicious wine and Michelin-star dining."
Drummond also suggested, "if your top priority is a high-end luxury resort, check out Cabo San Lucas, Mexico, for ocean-front extravagance, spas, yacht charters and 5-star all-inclusives that offer a better value than Vegas."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
10 minutes ago
- Associated Press
SRPT LEGAL ALERT: Lose Money on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)
NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317. Why Was Sarepta Sued for Securities Fraud? Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks. In truth, Elevidys causes fatal acute liver failure in some patients. The Stock Declines as the Truth Is Revealed On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or over 27%, from $101.35 per share on March 17, 2025, to $73.54 per share on March 18, 2025. Nevertheless, on the same day, Sarepta assured investors that 'the benefit-risk of ELEVIDYS remains positive.' Next, on June 15, 2025, Sarepta announced that a second patient treated with Elevidys had died from acute liver failure and that it was suspending certain shipments of Elevidys and paused dosing in an ongoing clinical trial of the treatment. On this news, the price of Sarepta stock fell $15.24 per share, or more than 42%, from $36.18 per share on June 13, 2025, to $20.94 per share on June 16, 2025. Finally, on July 17, 2025, Sarepta revealed that a third patient treated with one of Sarepta's investigational treatments related to Elevidys had died from acute liver failure in June 2025. On this news, the price of Sarepta stock fell more than 40% on July 18, 2025. Click here for more information: What Can You Do? If you invested in Sarepta you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.


Washington Post
10 minutes ago
- Washington Post
Two arrested as manhunt goes on for Tennessee quadruple murder suspect
Authorities in Tennessee arrested and charged two people with assisting a suspect in a quadruple murder case, as the high-profile search for the wanted man — whom they described as 'armed and dangerous' — entered a fourth day. The suspect, Austin Robert Drummond, 28, was charged with four counts of murder after three adults and a minor — all family members — were found dead in a wooded area in Tiptonville, western Tennessee, on Tuesday.


Associated Press
10 minutes ago
- Associated Press
SJM LEGAL ALERT: Lose Money on Your The J.M. Smucker Co. Investment? Contact BFA Law about its Securities Fraud Investigation (NYSE:SJM)
NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into The J.M. Smucker Company (NYSE: SJM) for potential violations of the federal securities laws. If you invested in J.M. Smucker, you are encouraged to obtain additional information by visiting: Why Is J.M. Smucker being Investigated? J.M. Smucker manufactures and markets branded food and beverage products. In November 2023, the company completed an acquisition of Hostess Brands, Inc., a manufacturer and marketer of sweet baked goods brands. The company stated that the Hostess acquisition was 'highly complementary' and that 'underlying trends in snacking and specifically sweet snacking still bode well for the category.' In truth, it appears the company's Sweet Baked Snacks segment, which includes Hostess, significantly deteriorated in the face of declining trends in sweet snacking. The Stock Declines as the Truth Is Revealed On June 10, 2025, J.M. Smucker reported its Q4 2025 financial results and announced that it recognized a $867 million impairment charge related to the goodwill of its Sweet Baked Snacks segment and a $113 million impairment charge related to the Hostess brand trademark driven by the 'continued underperformance of the Sweet Baked Snacks segment.' On this news, the price of J.M. Smucker stock fell $17.44 per share, or more than 18%, from $111.85 per share on June 9, 2025, to $94.41 per share on June 10, 2025. Click here for more information: What Can You Do? If you invested in J.M. Smucker you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.